A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
- Evidence population
- Human clinical study registration
- Participants
- 161
- Population
- ALL · 50 Years
- Duration
- 2022-06-30 to 2024-04-24
- Intervention
- EYP-1901; Aflibercept 2mg/0.05mL Inj,Oph
- Comparator
- Aflibercept
- Outcomes measured
- Average Change in Best Corrected Visual Acuity (BCVA) From Baseline Averaged Over Weeks 28 and 32 — Baseline (Day 1) an…; Change From Baseline in Best Corrected Visual Acuity up to Week 56 — Baseline (Day 1) and Weeks 32 and 56; Percentage of Subjects With >=5, >=10, and >=15 BCVA Letter Change From Baseline up to Week 56 — Baseline (Day 1) and W…; Percentage of Subjects Not Receiving Supplemental Injection of Aflibercept up to Week 56 — Weeks 32 and 56; Median Time to First Supplemental Aflibercept Injection in the Study Eye Following the EYP-1901 Dose at Week 8 — From W…; Number of Aflibercept Intravitreal Injections up to Week 56 (Including Loading Dose) — Weeks 32 and 56; Mean Change From Baseline in Central Subfield Thickness (CST) by Spectral-Domain - Optical Coherence Tomography (SD-OCT…; Change From Baseline in Height of Subretinal Fluid by Spectral-Domain - Optical Coherence Tomography up to Week 56 — Ba…; Percentage of Subjects With No Detectable Intraretinal Fluid/Cysts in the Central Subfield up to Week 56 — Weeks 32 and…; Change From Baseline in Total Lesion Area by Fluorescein Angiography (FA) up to Week 56 — Baseline (Day 1) and Weeks 32…; Change From Baseline in Total Choroidal Neovascularization Area by Fluorescein Angiography up to Week 56 — Baseline (Da…; Systemic Exposure to EYP-1901 Measured Through Plasma Levels up to Week 56 — Up to Week 56; Ocular Exposure to EYP-1901 Measured Through Aqueous Humor (AH) Levels up to Week 32 — Up to Week 32; Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events up to W…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 60% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 60%Source terminology contains: age-related macular degeneration. Source terminology supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.